566 related articles for article (PubMed ID: 17826043)
21. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
Betteridge DJ
Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
[TBL] [Abstract][Full Text] [Related]
22. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
23. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88].
Miranda VP; Rodrigues MJ; Gonçalves FR; Nunes JP
Rev Port Cardiol; 2009 Oct; 28(10):1099-119. PubMed ID: 20058777
[TBL] [Abstract][Full Text] [Related]
24. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
Donnelly R
Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
[TBL] [Abstract][Full Text] [Related]
25. [The best of epidemiology and cardiovascular prevention in 2006].
Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
[TBL] [Abstract][Full Text] [Related]
26. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
Edelman SV
Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701
[TBL] [Abstract][Full Text] [Related]
27. Potential cardiovascular benefits of insulin sensitizers.
Kunhiraman BP; Jawa A; Fonseca VA
Endocrinol Metab Clin North Am; 2005 Mar; 34(1):117-35. PubMed ID: 15752925
[TBL] [Abstract][Full Text] [Related]
28. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
[TBL] [Abstract][Full Text] [Related]
29. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes.
Boyne MS; Saudek CD
Diabetes Care; 1999 Apr; 22 Suppl 3():C45-53. PubMed ID: 10189562
[TBL] [Abstract][Full Text] [Related]
30. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
31. Optimizing cardiovascular outcomes in diabetes mellitus.
Sobel BE
Am J Med; 2007 Sep; 120(9 Suppl 2):S3-11. PubMed ID: 17826044
[TBL] [Abstract][Full Text] [Related]
32. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
33. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.
Lebovitz HE
Diabetes Care; 1999 Apr; 22 Suppl 3():C41-4. PubMed ID: 10189561
[TBL] [Abstract][Full Text] [Related]
34. Diabetes and cardiovascular risk markers.
Erdmann E
Curr Med Res Opin; 2005; 21 Suppl 1():S21-8. PubMed ID: 15811196
[TBL] [Abstract][Full Text] [Related]
35. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
Viberti G
J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
[TBL] [Abstract][Full Text] [Related]
36. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Lamanna C; Gori F; Marchionni N
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):604-12. PubMed ID: 19427768
[TBL] [Abstract][Full Text] [Related]
37. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance.
Mazzone T
Am J Cardiol; 2004 Jun; 93(11A):27C-31C. PubMed ID: 15178514
[TBL] [Abstract][Full Text] [Related]
38. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Polonsky T; Mazzone T; Davidson M
Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
[TBL] [Abstract][Full Text] [Related]
39. Diabetes mellitus and stroke.
Idris I; Thomson GA; Sharma JC
Int J Clin Pract; 2006 Jan; 60(1):48-56. PubMed ID: 16409428
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological treatment of diabetic patients with respect to prevention of macrovascular disease.
Tkác T
Acta Diabetol; 2003 Dec; 40 Suppl 2():S338-42. PubMed ID: 14704865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
